This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
burkitt-lymphoma
Burkitt Lymphoma
Burkitt lymphoma is a highly aggressive GC B-cell lymphoma defined by MYC translocation and near-100% Ki-67; endemic (EBV+), sporadic, immunodeficiency-associated subtypes; DA-EPOCH-R or R-CODOX-M/IVAC for adults; rituximab+LMB for pediatric; TLS prophylaxis essential.
Entry Metadata
| Field | Value |
|---|---|
| ID | burkitt-lymphoma |
| Name | Burkitt Lymphoma |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Roschewski M, Dunleavy K, Abramson JS, et al. Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma. J Clin Oncol. 2020;38(22):2519-2529. · PubMed 32530765
- Minard-Colin V, Auperin A, Pillon M, et al. Rituximab for children and adolescents with high-risk B-cell non-Hodgkin lymphoma: results of the randomized Inter-B-NHL Ritux 2010 trial. J Clin Oncol. 2022;40(22):2458-2471. · PubMed 35436151